PURPOSE: A prospective randomized trial was performed to determine if the addition of methotrexate, vinblastine, and doxorubicin to cisplatin (M-VAC) imparted a response rate or a survival advantage over single-agent cisplatin in patients with advanced urothelial carcinoma. PATIENTS AND METHODS: From October 1984 through May 1989, 269 patients with advanced urothelial carcinoma were entered onto this international intergroup trial and randomized to receive intravenous (IV) cisplatin (70 mg/m2) alone or with methotrexate (30 mg/m2 on days 1, 15, 22), vinblastine (3 mg/m2 on days 2, 15, 22) plus doxorubicin (30 mg/m2 on day 2). Cycles were repeated every 28 days until tumor progression or a maximum of six cycles. There were 246 fully assessable patients of whom 126 were randomized tocisplatin alone and 120 were randomized to the M-VAC regimen. RESULTS: As expected, the M-VAC regimen was associated with a greater toxicity, especially leukopenia, mucositis, granulocytopenic fever, and drug-related mortality. Response rates were superior for the M-VAC regimen compared with single-agent cisplatin (39% v 12%; P less than .0001). Similarly, the progression-free survival (10.0 v 4.3 months) and overall survival (12.5 v 8.2 months) were significantly greater for the combined therapy arm. CONCLUSION: Although a more toxic regimen, we found M-VAC to be superior to single-agent cisplatin with respect to response rate, duration of remission, and overall survival in patients with advanced urothelial carcinoma.
RCT Entities:
PURPOSE: A prospective randomized trial was performed to determine if the addition of methotrexate, vinblastine, and doxorubicin to cisplatin (M-VAC) imparted a response rate or a survival advantage over single-agent cisplatin in patients with advanced urothelial carcinoma. PATIENTS AND METHODS: From October 1984 through May 1989, 269 patients with advanced urothelial carcinoma were entered onto this international intergroup trial and randomized to receive intravenous (IV) cisplatin (70 mg/m2) alone or with methotrexate (30 mg/m2 on days 1, 15, 22), vinblastine (3 mg/m2 on days 2, 15, 22) plus doxorubicin (30 mg/m2 on day 2). Cycles were repeated every 28 days until tumor progression or a maximum of six cycles. There were 246 fully assessable patients of whom 126 were randomized to cisplatin alone and 120 were randomized to the M-VAC regimen. RESULTS: As expected, the M-VAC regimen was associated with a greater toxicity, especially leukopenia, mucositis, granulocytopenic fever, and drug-related mortality. Response rates were superior for the M-VAC regimen compared with single-agent cisplatin (39% v 12%; P less than .0001). Similarly, the progression-free survival (10.0 v 4.3 months) and overall survival (12.5 v 8.2 months) were significantly greater for the combined therapy arm. CONCLUSION: Although a more toxic regimen, we found M-VAC to be superior to single-agent cisplatin with respect to response rate, duration of remission, and overall survival in patients with advanced urothelial carcinoma.
Authors: Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Robert Jones; Jacqueline Vuky; Tony Elliott; Graham Mead; José Angel Arranz; John Chester; Simon Chowdhury; Arkadiusz Z Dudek; Volker Müller-Mattheis; Marc-Oliver Grimm; Jürgen E Gschwend; Christian Wülfing; Peter Albers; Jianguo Li; Anna Osmukhina; Jeffrey Skolnik; Gary Hudes Journal: Invest New Drugs Date: 2013-01-18 Impact factor: 3.850
Authors: J Lehmann; M Retz; G Steiner; P Albers; E Jaeger; A Knuth; C Lippert; M Koser; K Stockamp; C Otto; H Melchior; C Fassmann; C Potratz; T Loch; H G Derigs; T Becker; T Kälble; H-J Piechota; L Hertle; S Weinknecht; L Weissbach; M Al-Mwalad; A Hamza; H Henss; D Brkovic; S Pomer; J Roloff; P Walz; R Muschter; U Tunn; E Winter; P Bub; U Kaldenbach; S Roth; A Brauers; G Jakse; A E Richter; M Wirth; J Hartlapp; H Van Ahlen; M Stöckle Journal: Urologe A Date: 2003-04-02 Impact factor: 0.639
Authors: Chris Protzel; Uwe Zimmermann; Elke Asse; Gerhard Kallwellis; Klaus Juergen Klebingat Journal: J Neurooncol Date: 2002-04 Impact factor: 4.130